M
Morris Sherman
Researcher at Chang Gung University
Publications - 3
Citations - 7444
Morris Sherman is an academic researcher from Chang Gung University. The author has contributed to research in topics: Hepatocellular carcinoma & Sorafenib. The author has an hindex of 3, co-authored 3 publications receiving 7403 citations.
Papers
More filters
AASLD PRACTICE GUIDELINE Management of Hepatocellular Carcinoma: An Update
Jordi Bruix,Morris Sherman +1 more
TL;DR: Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated.
Journal ArticleDOI
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
Josep M. Llovet,Thomas Decaens,Jean-Luc Raoul,Eveline Boucher,Masatoshi Kudo,Charissa Chang,Yoon-Koo Kang,Eric Assenat,H. Y. Lim,Valérie Boige,Philippe Mathurin,Laetitia Fartoux,Deng-Yn Lin,Jordi Bruix,Ronnie T.P. Poon,Morris Sherman,J.-F. Blanc,Richard S. Finn,Won Young Tak,Yee Chao,Rana Ezzeddine,David R. Liu,Ian Walters,Joong-Won Park +23 more
TL;DR: In patients with HCC who had been treated with sorafenib, brivanib did not significantly improve OS, and the observed benefit in the secondary outcomes of TTP and ORR warrants further investigation.